Literature DB >> 27403315

Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: how should rifabutin be managed in rescue regimens?

Giuseppe Losurdo1, Andrea Iannone1, Floriana Giorgio1, Mariabeatrice Principi1, Alfredo Di Leo1, Enzo Ierardi1.   

Abstract

Entities:  

Keywords:  Helicobacter pylori; antibiotic resistance; rescue regimens; rifabutin

Year:  2015        PMID： 27403315      PMCID： PMC4924442          DOI： 10.1177/2050640615623697

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN： 2050-6406            Impact factor:   4.623


× No keyword cloud information.
  11 in total

Review 1.  Resistance of Helicobacter pylori to antibiotics and its impact on treatment options.

Authors:  F Mégraud
Journal:  Drug Resist Updat       Date:  2001-06       Impact factor: 18.500

2.  Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report.

Authors:  Peter Malfertheiner; Francis Megraud; Colm A O'Morain; John Atherton; Anthony T R Axon; Franco Bazzoli; Gian Franco Gensini; Javier P Gisbert; David Y Graham; Theodore Rokkas; Emad M El-Omar; Ernst J Kuipers
Journal:  Gut       Date:  2012-05       Impact factor: 23.059

3.  Outcomes from treating tuberculosis with rifampicin or rifabutin in HIV-infected persons also receiving antiretroviral therapy.

Authors:  Timothy M Rawson; Nataliya Brima; Fahad Almajid; Anton L Pozniak; Azara Janmohamed; Sundhiya Mandalia; Sheena Basnayake; Lusha Kellgren; Andrew J Copas; Robert F Miller
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

Review 4.  Review article: rifabutin in the treatment of refractory Helicobacter pylori infection.

Authors:  J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2011-11-30       Impact factor: 8.171

5.  Quadruple rescue therapy after first and second line failure for Helicobacter pylori treatment: comparison between two tetracycline-based regimens.

Authors:  Enzo Ierardi; Antonio Giangaspero; Giuseppe Losurdo; Floriana Giorgio; Annacinzia Amoruso; Vincenzo De Francesco; Alfredo Di Leo; Mariabeatrice Principi
Journal:  J Gastrointestin Liver Dis       Date:  2014-12       Impact factor: 2.008

6.  Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.

Authors:  S Miehlke; K Hansky; W Schneider-Brachert; C Kirsch; A Morgner; A Madisch; E Kuhlisch; E Bästlein; E Jacobs; E Bayerdörffer; N Lehn; M Stolte
Journal:  Aliment Pharmacol Ther       Date:  2006-07-15       Impact factor: 8.171

7.  Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015.

Authors:  Rocco Maurizio Zagari; Marco Romano; Veronica Ojetti; Reinhold Stockbrugger; Sergio Gullini; Bruno Annibale; Fabio Farinati; Enzo Ierardi; Giovanni Maconi; Massimo Rugge; Carlo Calabrese; Francesco Di Mario; Francesco Luzza; Stefano Pretolani; Antonella Savio; Giovanni Gasbarrini; Michele Caselli
Journal:  Dig Liver Dis       Date:  2015-07-06       Impact factor: 4.088

Review 8.  How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography?

Authors:  Enzo Ierardi; Floriana Giorgio; Giuseppe Losurdo; Alfredo Di Leo; Mariabeatrice Principi
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

9.  Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease.

Authors:  D E Griffith; B A Brown; W M Girard; R J Wallace
Journal:  Clin Infect Dis       Date:  1995-09       Impact factor: 9.079

Review 10.  Culture-guided treatment approach for Helicobacter pylori infection: review of the literature.

Authors:  Giovanni Cammarota; Gianluca Ianiro; Stefano Bibbò; Teresa Antonella Di Rienzo; Luca Masucci; Maurizio Sanguinetti; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742
View more
  1 in total

Review 1.  Current Status of the Third-Line Helicobacter pylori Eradication.

Authors:  Jae Ho Choi; Young Joo Yang; Chang Seok Bang; Jae Jun Lee; Gwang Ho Baik
Journal:  Gastroenterol Res Pract       Date:  2018-05-02       Impact factor: 2.260
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.